Drug Profile
SNS 01
Alternative Names: SNS 101; SNS-01; SNS-01-TLatest Information Update: 04 Jan 2018
Price :
$50
*
At a glance
- Originator Senesco Technologies
- Developer Senesco Technologies; Sevion Therapeutics
- Class Antineoplastics; Gene therapies; Small interfering RNA
- Mechanism of Action Apoptosis stimulants; Cell adhesion molecule inhibitors; Eukaryotic initiation factor 5A modulators; NF-kappa B inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bladder cancer; Diffuse large B cell lymphoma; Lung cancer; Mantle-cell lymphoma; Multiple myeloma
Most Recent Events
- 17 Nov 2014 Suspended - Phase-I/II for Diffuse large B cell lymphoma (Second-line therapy or greater) in South Africa (IV)
- 17 Nov 2014 Suspended - Phase-I/II for Diffuse large B cell lymphoma (Second-line therapy or greater) in USA (IV)
- 17 Nov 2014 Suspended - Phase-I/II for Mantle cell lymphoma (Second-line therapy or greater) in South Africa (IV)